November 11, 2020
Eisai and US Merck said on November 10 that their Lenvima (lenvatinib)-Keytruda (pembrolizumab) combination therapy demonstrated a significant survival benefit over Sutent (sunitinib) as a frontline treatment for advanced renal cell carcinoma. According to topline results from the pivotal PIII...read more